About the Webinar
Nodal T-follicular helper cell lymphoma (nTFHL) is a prevalent subtype of T-cell lymphoma with a dismal 5-year overall survival rate of 30-40%. While previous studies have highlighted recurrent alterations in epigenetic modifier genes, the direct impact of 3D chromatin architecture on the gene expression changes driving T-cell lymphomagenesis remains poorly understood.
In this webinar, you’ll learn how Hi-C sequencing uncovers nTFHL-specific alterations in chromatin organization and enhancer-promoter interactions, offering novel insights into the molecular underpinnings of nTFHL.
Register Now
What Will You Learn?
- How distinct chromatin conformations create a lymphoma-specific gene regulatory landscape in TFHL.
- The role of promoter-super enhancer/enhancer loops in driving aberrant gene regulation in nTFHL.
Meet the Speakers
![](https://arimagenomics.com/wp-content/files/Makoto-Iwasaki-1.png)
Makoto Iwasaki, MD, PhD
Massachusetts General Hospital Cancer CenterMakoto is a hematologist and post-doctoral research fellow in Dr. Salvia Jain’s Laboratory at the Massachusetts General Hospital Cancer Center. He received his MD and PhD from Kyoto University, Japan. Makoto's research focuses on advancing translational research in hematological malignancies through data-driven approaches including multi-omic analysis and machine learning to unravel gene regulatory mechanisms and their clinical implications. Currently, he is investigating the role of 3D chromatin organization in the development of T-cell lymphoma, with the ultimate goal of identifying novel therapeutic targets.
![](https://arimagenomics.com/wp-content/files/Webinar-Speaker-Bio-Photos-1-1.png)
Anthony Schmitt, PhD
Arima GenomicsAnthony is the SVP of Science at Arima Genomics, where his expertise in 3D genomics has been pivotal to the company's development of Hi-C technology and its applications in genomics research. He received his PhD from the University of California, San Diego, where he developed novel methodologies for understanding gene regulation using 3D genomics approaches. Since Arima’s inception, Anthony has led the development of the core Arima Hi-C chemistry and technology platform, as well as industry partnerships and academic collaborations.